Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy

Cancer

Volumn 77, Issue 2, 1996, Pages 292-300

  Chevillard, Sylvie ^a   Pouillart, Pierre ^a   Beldjord, Chérif ^b   Asselain, Bernard ^a   Beuzeboc, Philippe ^a   Magdelénat, Henri ^a   Vielh, Philippe ^a  

^a INSTITUT CURIE   (France)

^b CHU Cochin Port Royal ^*  (France)

Author keywords

breast cancer; multidrug resistance; neoadjuvant chemotherapy; S phase fraction

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; THIOTEPA;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE S PHASE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA PRIMERS; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES; HUMANS; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, NEOPLASM; S PHASE;

EID: 0030045286     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X     Document Type: Article

References (34)

1. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-45.
2. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-52.
3. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelénat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J Natl Cancer Inst 1989;81:1383-7.
4. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701.
5. Ro J, Sahin A, Ro JY, Fritsche H, Hoitobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990;21:787-91.
6. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T, et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990;62:758-61.
7. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;83:111-6.
8. Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, et al. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 1991;27:1352-5.
9. Fojo AT, Ueda K. Slamon DJ, Poplack DG, Gottesman MM, Pastan I, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-9.
10. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
11. Roninson IB. Molecular and cellular biology of multidrug resistance in tumor cells. New York: Plenum Press, 1991.
12. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
13. Dalton WS, Grogan TM, Rybski JA. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989;73:747-52.
14. Goldstein LJ, Fojo AT, Ueda K, Willingham M, Lai SL, Gazdar A, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncal 1990;8:128-36.
15. Chan H, Haddad G, Thorner P, DeBoer G, Lin Y, Ondrusek N, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
16. Chevillard S, Vielh P, Bastian G, Coppey J. A single 24 h contact time with adriamycin provokes the emergence of resistant cells expressing the Gp 170 protein. Anticancer Res 1992;12:495-500.
17. Vielh P, Magdelénat H, Mosseri V, Remvikos Y, Di Bonito L. Immunocytochemical determination of estrogen and progesterone receptors on 50 fine-needle samples of breast cancer: a prospective study including biochemical correlation and DNA flow cytometric analysis. Am J Clin Pathol 1992;97:254-61.
18. Hermanek P, Sobin LH, editors. UICC TNM Classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer-Verlag, 1992.
19. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles & practice of oncology. 4th ed. Philadelphia: J B Lippincott Co., 1993;1264-1332.
20. World Health Organization. International histologic classification of tumours. Geneva: World Health Organization, 1969-1981. 2nd ed. Berlin: Springer-Verlag, 1988-Present.
21. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed 15 years. Br J Cancer 1957;11:359-77.
22. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and characterization of human KB cell lines to multiple drugs. Somat Cell Mol Genet 1985;11:117-26.
23. Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics. East Norwalk: Appleton & Lange, 1990.
24. Remvikos Y, Jouve M, Beuzeboc P, Vielh P, Magdelénat H, Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993;29A;1843-8.
25. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986;261:15544-9.
26. Frishe E, Danks M, Schmidt C, Beck W. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 1991;51:4213-8.
27. Fine RL, Patel J, Chabner BA. Phorbol ester induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988;85:582-6.
28. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance mdrl gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6.
29. Hill B, Deuchars K, Hosking L, Ling V, Whelan R. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 1990;82:607-12.
30. Chaudhary PM, Roninson I. Induction of multidrug resistance in human cells by transient exposure to different che-motherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
31. Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for p-glycoprotein overexpression or gene amplification. J Clin Oncol 1989;7:1129-36.
32. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989;60:815-8.
33. Thiebault F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localisation in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localisation in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37:159-64.
34. Vallabhaneni VR, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyravate carboxylase. Cancer Res 1994;54:1536-41.